Psychoeducation for Drug Addiction
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new approach called the Metacognium software app, designed to help individuals with substance use disorders (SUDs) improve their awareness of their own thinking and decision-making. The researchers aim to determine if this app can enhance understanding and management of addiction, potentially leading to better treatment outcomes. Participants will either use the app alongside their usual treatment or continue with their usual treatment alone. Suitable candidates for this trial include those currently receiving treatment for opioid or stimulant use disorders and who have a smartphone that supports the app. As an unphased trial, this study offers a unique opportunity to explore innovative treatment options that could enhance the recovery journey.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it requires participants to be on medication treatment for substance use disorder, so you may need to continue those medications.
What prior data suggests that the Metacognium software app is safe for use in treating substance use disorders?
Research has shown that the Metacognium app, used in this trial, is designed to enhance mental strength and self-awareness. While specific safety data from trials remains limited, the app targets adults, including college students, to aid in stress management, suggesting it is generally safe and well-tolerated. As this trial emphasizes education on mental processes, it is unlikely to cause physical harm. Consulting a healthcare professional is advisable to determine if participation is suitable.12345
Why are researchers excited about this trial?
Researchers are excited about the Metacognium software app because it offers a fresh approach to tackling drug addiction through psychoeducation. Unlike typical treatments that rely heavily on medications like buprenorphine or traditional therapy sessions, Metacognium uses technology to deliver interactive and engaging 20-minute sessions. This app-based intervention aims to enhance cognitive processes and decision-making skills, which could lead to more sustainable recovery outcomes. By integrating this digital tool with standard care, there's potential to enrich and personalize the treatment experience for individuals struggling with addiction.
What evidence suggests that the Metacognium software app is effective for improving metacognition in substance use disorders?
Research shows that the Metacognium app, available to participants in this trial, can help individuals better understand and manage their thinking. This capability can lead to smarter choices regarding drug and alcohol use. Studies have found that increased awareness of one's thoughts may reduce the likelihood of risky substance use. The app could also boost confidence in avoiding drugs and alcohol. However, more research is needed to fully understand its impact on views about drug use. Early results suggest the app could be a valuable tool for those recovering from substance use problems.24678
Who Is on the Research Team?
Jasmin Vassileva, Ph.D.
Principal Investigator
Virginia Commonwealth University
Are You a Good Fit for This Trial?
This trial is for individuals with opioid and/or stimulant use disorder who are currently on medication treatment for SUD. Participants must own a smartphone capable of using the NIPA app. People with current psychosis, mania, or suicidal/homicidal ideation, or those who do not speak English cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the NIPA program, consisting of four 20-minute sessions administered a week apart, alongside treatment as usual (TAU)
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Metacognium software app
Find a Clinic Near You
Who Is Running the Clinical Trial?
Virginia Commonwealth University
Lead Sponsor